Comparison of outcomes of HCT in blast phase of BCR-ABL1- MPN with de novo AML and with AML following MDS

↓ Direkt till sidans innehåll
↓ Direkt till sidans sekundära innehåll (sidomenyn)

Sökning: onr:"swepub:oai:DiVA.org:uu-426813" > Comparison of outco...

1 av 1
Föregående post
Nästa post
Till träfflistan

LIBRIS Formathandbok (Information om MARC21)

Fältnamn	Indikatorer	Metadata
000		08602naa a2200829 4500
001		oai:DiVA.org:uu-426813
003		SwePub
008		201202s2020 \| \|\|\|\|\|\|\|\|\|\|\|000 \|\|eng\|
009		oai:prod.swepub.kib.ki.se:145109566
024	7	a https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-4268132 URI
024	7	a https://doi.org/10.1182/bloodadvances.20200026212 DOI
024	7	a http://kipublications.ki.se/Default.aspx?queryparsed=id:1451095662 URI
040		a (SwePub)uud (SwePub)ki
041		a engb eng
042		9 SwePub
072	7	a ref2 swepub-contenttype
072	7	a art2 swepub-publicationtype
100	1	a Gupta, Vikasu Princess Margaret Canc Ctr, 700 Univ Ave,6-326, Toronto, ON M5G 1Z5, Canada.4 aut
245	1 0	a Comparison of outcomes of HCT in blast phase of BCR-ABL1- MPN with de novo AML and with AML following MDS
264		c 2020-10-02
264	1	b American Society of Hematology,c 2020
338		a print2 rdacarrier
520		a Comparative outcomes of allogeneic hematopoietic cell transplantation (HCT) for BCR-ABL12 myeloproliferative neoplasms (MPNs) in blast phase (MPN-BP) vs de novo acute myeloid leukemia (AML), and AML with prior myelodysplastic syndromes (MDSs; post-MDS AML), are unknown. Using the Center for International Blood and Marrow Transplant Research (CIBMTR) database, we compared HCT outcomes in 177 MPN-BP patients with 4749 patients with de novo AML, and 1104 patients with post-MDS AML, using multivariate regression analysis in 2 separate comparisons. In a multivariate Cox model, no difference in overall survival (OS) or relapse was observed in patients with MPN-BP vs de novo AML with active leukemia at HCT. Patients with MPN-BP in remission had inferior OS in comparison with de novo AML in remission (hazard ratio [HR], 1.40 [95% confidence interval [ CI], 1.12-1.76]) due to higher relapse rate (HR, 2.18 [95% CI, 1.69-2.80]). MPN-BP patients had inferior OS (HR, 1.19 [95% CI, 1.00-1.43]) and increased relapse (HR, 1.60 [95% CI, 1.31-1.96]) compared with post-MDS AML. Poor-risk cytogenetics were associated with increased relapse in both comparisons. Peripheral blood grafts were associated with decreased relapse in MPN-BP and post-MDS AML (HR, 0.70 [95% CI, 0.57-0.86]). Nonrelapse mortality (NRM) was similar between MPN-BP vs de novo AML, and MPN-BP vs post-MDS AML. Total-body irradiation-based myeloablative conditioning was associated with higher NRM in both comparisons. Survival of MPN-BP after HCT is inferior to de novo AML in remission and post-MDS AML due to increased relapse. Relapse-prevention strategies are required to optimize HCT outcomes in MPN-BP.
650	7	a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Hematologi0 (SwePub)302022 hsv//swe
650	7	a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Hematology0 (SwePub)302022 hsv//eng
700	1	a Kim, Soyoungu Med Coll Wisconsin, Dept Med, Ctr Int Blood & Marrow Transplant Res CIBMTR, Milwaukee, WI 53226 USA.;Med Coll Wisconsin, Div Biostat, Inst Hlth & Equ, Milwaukee, WI 53226 USA.4 aut
700	1	a Hu, Zhen-Huanu Med Coll Wisconsin, Dept Med, Ctr Int Blood & Marrow Transplant Res CIBMTR, Milwaukee, WI 53226 USA.4 aut
700	1	a Liu, Yingu Columbia Univ, Dept Psychiat, Mental Hlth Data Sci, Irving Med Ctr, New York, NY USA.4 aut
700	1	a Aljurf, Mahmoudu King Faisal Specialist Hosp Ctr & Res Ctr, Dept Oncol, Riyadh, Saudi Arabia.4 aut
700	1	a Bacher, Ulrikeu Univ Bern, Bern Univ Hosp, Dept Hematol, Inselspital, Bern, Switzerland.4 aut
700	1	a Beitinjaneh, Ameru Univ Miami, Div Transplantat & Cellular Therapy, Miami, FL USA.4 aut
700	1	a Cahn, Jean-Yvesu Ctr Hosp Univ CHU Grenoble Alpes, Dept Hematol, Grenoble, France.4 aut
700	1	a Cerny, Janu Univ Massachusetts, Med Ctr, Dept Med, Div Hematol Oncol, Worcester, MA USA.4 aut
700	1	a Copelan, Edwardu Atrium Hlth, Dept Hematol Oncol & Blood Disorders, Levine Canc Inst, Charlotte, NC USA.4 aut
700	1	a Gadalla, Shahinaz M.u NCI, Div Canc Epidemiol & Genet, Clin Genet Branch, NIH, Rockville, MD USA.4 aut
700	1	a Gale, Robert Peteru Imperial Coll London, Haematol Res Ctr, Dept Immunol & Inflammat, London, England.4 aut
700	1	a Ganguly, Siddharthau Univ Kansas Hlth Syst, Div Hematol Malignancy & Cellular Therapeut, Kansas City, KS USA.4 aut
700	1	a George, Bijuu Christian Med Coll & Hosp, Vellore, Tamil Nadu, India.4 aut
700	1	a Gerds, Aaron T.u Cleveland Clin, Taussig Canc Inst, Hematol & Med Oncol, Cleveland, OH 44106 USA.4 aut
700	1	a Gergis, Usamau Thomas Jefferson Univ, Div Hematol Malignancies, Dept Med Oncol, Philadelphia, PA 19107 USA.4 aut
700	1	a Hamilton, Betty K.u Cleveland Clin, Taussig Canc Inst, Blood & Marrow Transplant Program, Cleveland, OH 44106 USA.4 aut
700	1	a Hashmi, Shahrukhu Mayo Clin, Dept Internal Med, Rochester, MN USA.;King Faisal Specialist Hosp & Res Ctr, Oncol Ctr, Riyadh, Saudi Arabia.4 aut
700	1	a Hildebrandt, Gerhard C.u Univ Kentucky, Markey Canc Ctr, Lexington, KY USA.4 aut
700	1	a Kamble, Rammurti T.u Baylor Univ, Coll Med, Ctr Cell & Gene Therapy, Div Hematol & Oncol, Houston, TX USA.4 aut
700	1	a Kindwall-Keller, Tamilau Univ Virginia Hlth Syst, Div Hematol Oncol, Charlottesville, VA USA.4 aut
700	1	a Lazarus, Hillard M.u Case Western Reserve Univ, Cleveland Med Ctr, Univ Hosp, Cleveland, OH 44106 USA.4 aut
700	1	a Liesveld, Jane L.u Univ Rochester, Med Ctr, Dept Med, Rochester, NY 14642 USA.4 aut
700	1	a Litzow, Marku Mayo Clin Rochester, Div Hematol & Transplant Ctr, Rochester, MN USA.4 aut
700	1	a Maziarz, Richard T.u Oregon Hlth & Sci Univ, Knight Canc Inst, Adult Blood & Marrow Stem Cell Transplant Program, Portland, OR 97201 USA.4 aut
700	1	a Nishihori, Taigau H Lee Moffitt Canc Ctr & Res Inst, Dept Blood & Marrow Transplant & Cellular Immunot, Tampa, FL USA.4 aut
700	1	a Olsson, Richardu Uppsala universitet,Centrum för klinisk forskning i Sörmland (CKFD),Karolinska Inst, Dept Lab Med, Stockholm, Sweden4 aut0 (Swepub:uu)riols677
700	1	a Rizzieri, Davidu Duke Univ, Div Hematol Malignancies & Cellular Therapy, Durham, NC USA.4 aut
700	1	a Savani, Bipin N.u Vanderbilt Univ, Med Ctr, Dept Med, Div Hematol Oncol, Nashville, TN USA.4 aut
700	1	a Seo, Sachikou Dokkyo Med Univ, Dept Hematol & Oncol, Mibu, Tochigi, Japan.4 aut
700	1	a Solh, Melhemu Northside Hosp, Blood & Marrow Transplant Grp Georgia, Atlanta, GA USA.4 aut
700	1	a Szer, Jeffu Royal Melbourne Hosp, Clin Haematol, Peter MacCallum Canc Ctr, Melbourne, Vic, Australia.4 aut
700	1	a Verdonck, Leo F.u Isala Clin, Dept Hematol Oncol, Zwolle, Netherlands.4 aut
700	1	a Wirk, Baldeepu Penn State Canc Inst, Bone Marrow Transplant Program, Hershey, PA USA.4 aut
700	1	a Woolfrey, Annu Fred Hutchinson Canc Res Ctr, 1124 Columbia St, Seattle, WA 98104 USA.4 aut
700	1	a Yared, Jean A.u Univ Maryland, Dept Med, Greenebaum Comprehens Canc Ctr, Blood & Marrow Transplantat Program,Div Hematol O, Baltimore, MD 21201 USA.4 aut
700	1	a Alyea, Edwin P.u Dana Farber Canc Inst, Ctr Hematol Oncol, Boston, MA 02115 USA.4 aut
700	1	a Popat, Uday R.u Univ Texas MD Anderson Canc Ctr, Dept Stem Cell Transplantat & Cellular Therapy, Div Canc Med, Houston, TX 77030 USA.4 aut
700	1	a Sobecks, Ronald M.u Cleveland Clin, Hematol & Med Oncol, Cleveland, OH 44106 USA.4 aut
700	1	a Scott, Bart L.u Fred Hutchinson Canc Res Ctr, 1124 Columbia St, Seattle, WA 98104 USA.4 aut
700	1	a Nakamura, Ryotarou City Hope Natl Med Ctr, Dept Hematol & Hematopoiet Cell Transplantat, Duarte, CA USA.4 aut
700	1	a Saber, Waelu Med Coll Wisconsin, Dept Med, Ctr Int Blood & Marrow Transplant Res CIBMTR, Milwaukee, WI 53226 USA.4 aut
710	2	a Princess Margaret Canc Ctr, 700 Univ Ave,6-326, Toronto, ON M5G 1Z5, Canada.b Med Coll Wisconsin, Dept Med, Ctr Int Blood & Marrow Transplant Res CIBMTR, Milwaukee, WI 53226 USA.;Med Coll Wisconsin, Div Biostat, Inst Hlth & Equ, Milwaukee, WI 53226 USA.4 org
773	0	t Blood Advancesd : American Society of Hematologyg 4:19, s. 4748-4757q 4:19<4748-4757x 2473-9529x 2473-9537
856	4	u https://ashpublications.org/bloodadvances/article-pdf/4/19/4748/1807416/advancesadv2020002621.pdf
856	4 8	u https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-426813
856	4 8	u https://doi.org/10.1182/bloodadvances.2020002621
856	4 8	u http://kipublications.ki.se/Default.aspx?queryparsed=id:145109566

Hitta via bibliotek

Blood Advances (Sök värdpublikationen i LIBRIS)

Till lärosätets databas

1 av 1
Föregående post
Nästa post
Till träfflistan

Hitta mer i SwePub

Om ämnet

MEDICIN OCH HÄLSOVETENSKAP: MEDICIN OCH HÄLS ...; och Klinisk medicin; och Hematologi

Artiklar i publikationen: Blood Advances

Av lärosätet: Uppsala universitet; Karolinska Institutet

Sök utanför SwePub

Sök vidare i:: Google; Google Book Search; Google Scholar

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

LIBRIS.kb.se